OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2026
- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2026.
As previously announced, the Company has entered into a definitive merger agreement pursuant to which it will be acquired by Clayton, Dubilier & Rice, LLC and McKesson Corporation. Given the pending acquisition, the Company will not host an earnings conference call in connection with these results and has withdrawn its previously disclosed financial guidance.
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 8,000 team members, including more than 5,000 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at optioncarehealth.com.
Bob Okunski Vice President, Investor Relations [email protected]
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company may make regarding the acquisition, future revenues, future earnings, other future financial results, regulatory developments, market developments, new products and growth strategies and the effects of any of the foregoing on its future results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. The Company's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, including circumstances requiring the Company to pay a termination fee pursuant to the merger agreement, or the inability to complete the proposed transaction on the anticipated terms and timetable; the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of the Company or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; costs related to the proposed transaction, including from potential litigation relating to the proposed transaction; the risk that restrictions on the operation of the Company’s business during the pendency of the proposed transaction may impact the Company’s ability to pursue certain business opportunities or strategic transactions or undertake certain actions the Company might otherwise have taken; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of the Company’s common stock, credit ratings or operating results; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel, retain customers and maintain relationships with business partners, suppliers and customers; the diversion of management’s time and attention from ordinary course business operations to completion of the proposed transaction; changes in laws, regulations or trade policies applicable to its business model; loss of relationships with managed care organizations and other non-governmental third party payers; changes in the pharmaceutical industry, including limiting or discontinuing research, development, production and marketing of pharmaceuticals compatible with its services; changes in market conditions and receptivity to its services and offerings; and pending and future litigation or potential liability for claims not covered by insurance. The foregoing review of important factors should not be construed as exhaustive. Additional information concerning risks, uncertainties and assumptions can be found in the Company’s filings with the SEC, including the risk factors discussed in the Company’s most recent Annual Report on Form 10-K, as updated by the Company’s Quarterly Reports on Form 10-Q and future filings with the SEC.
Any forward-looking statement made by the Company in this press release is based only on information currently available to it and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted net income, Adjusted EBITDA and Adjusted diluted earnings per share ("EPS"), which are non-GAAP financial measures. These adjusted measures are not measurements of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, EPS, or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definitions of Adjusted net income, Adjusted EBITDA, and Adjusted diluted EPS may not be comparable to similarly titled non-GAAP financial measures reported by other companies. As defined by the Company: (i) Adjusted net income represents net income before intangible asset amortization expense, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, net of tax adjustments, (ii) Adjusted EBITDA represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other expenses, and (iii) Adjusted diluted EPS represents Adjusted net income divided by weighted average common shares outstanding, diluted. As part of restructuring, acquisition, integration and other expenses, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, certain litigation expenses and reserves related to acquired businesses, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that these adjusted measures provide useful supplemental information regarding the performance of Option Care Health’s business operations and facilitate comparisons to the Company’s historical operating results. The Company has not reconciled Adjusted EBITDA guidance to net income or Adjusted diluted EPS guidance to GAAP diluted EPS as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. Full reconciliations of each historical adjusted measure to the most comparable GAAP financial measure are set forth below. Schedule 1
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── ASSETS CURRENT ASSETS: Cash and cash equivalents $ 299,093 $ 232,624 Accounts receivable, net 505,568 473,566 Inventories 408,045 471,149 Prepaid expenses and other current 99,385 87,629 assets Total current assets 1,312,091 1,264,968 NONCURRENT ASSETS: Property and equipment, net 139,035 139,236 Intangible assets, net 19,394 21,897 Referral sources, net 261,975 287,281 Goodwill 1,606,743 1,606,743 Other noncurrent assets 137,029 135,644 Total noncurrent assets 2,164,176 2,190,801 TOTAL ASSETS $ 3,476,267 $ 3,455,769 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 670,676 $ 639,829 Other current liabilities 179,854 189,519 Total current liabilities 850,530 829,348 NONCURRENT LIABILITIES: Long-term debt, net of discount, deferred financing costs 1,151,054 1,154,052 and current portion Other noncurrent 150,205 145,976 liabilities Total noncurrent 1,301,259 1,300,028 liabilities Total liabilities 2,151,789 2,129,376 STOCKHOLDERS' EQUITY 1,324,478 1,326,393 TOTAL LIABILITIES AND STOCKHOLDERS' $ 3,476,267 $ 3,455,769 EQUITY
Nine Months Ended CASH FLOWS FROM September 30, OPERATING ACTIVITIES: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 156,689 $ 149,081 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 52,874 50,374 amortization expense Other non-cash 54,243 57,401 adjustments Changes in operating assets and liabilities: Accounts receivable, -32,002 -55,430 net Inventories 63,104 -24,899 Prepaid expenses and other current -14,933 24,694 assets Accounts payable 31,824 10,224 Accrued compensation and employee -8,069 8,338 benefits Other -17,518 2,773 Net cash provided by operating 286,212 222,556 activities CASH FLOWS FROM INVESTING ACTIVITIES: Acquisition of -26,805 -27,661 property and equipment Business acquisitions, net of cash — -117,247 acquired Other investing -877 -2,529 activities Net cash used in -27,682 -147,437 investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Purchase of company stock and related -170,545 -214,887 excise taxes Proceeds from issuance — 229,472 of debt Retirement of debt — -180,239 obligations Other financing -21,516 -12,208 activities Net cash used in -192,061 -177,862 financing activities NET INCREASE (DECREASE) IN CASH AND 66,469 -102,743 CASH EQUIVALENTS Cash and cash equivalents - 232,624 412,565 beginning of period CASH AND CASH EQUIVALENTS - END OF $ 299,093 $ 309,822 PERIOD
(1) Restructuring, acquisition, integration and other includes $5,640 and $13,796 of operating expenses for the three and nine months ended September 30, 2026, respectively. Restructuring, acquisition, integration and other includes $4,634 and $12,570 of operating expenses for the three and nine months ended September 30, 2025, respectively.
(2) Beginning with the three months ended September 30, 2025, adjusted net income excludes loss on extinguishment of debt on a prospective basis, which has been immaterial in prior periods.
(3) Tax adjustments for the three and nine months ended September 30, 2026 and 2025 include the estimated income tax effect on non-GAAP adjustments based on the effective tax rate.
Full text with the tables
Exhibit 99.1
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED
SEPTEMBER 30, 2026
BANNOCKBURN, IL., November 4, 2026
- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq:
OPCH), the nation’s largest independent provider of home and alternate site
infusion services, announced today financial results for the third quarter ended
September 30, 2026.
Third Quarter 2026 Financial Highlights
(year-over-year comparisons unless otherwise noted)
• Net revenue of $1,493.5 million, up 4.1%
• GAAP net income of $57.4 million, up 10.8%
• GAAP diluted earnings per share of $0.38, up 18.8%
• Adjusted EBITDA of $124.6 million, up 4.3%
• Adjusted diluted earnings per share of $0.49, up 8.9%
• Cash provided by Q3 operating activities of $114.7 million
As previously announced, the Company has entered into a definitive merger
agreement pursuant to which it will be acquired by Clayton, Dubilier & Rice, LLC
and McKesson Corporation. Given the pending acquisition, the Company will not
host an earnings conference call in connection with these results and has
withdrawn its previously disclosed financial guidance.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and
alternate site infusion services. With over 8,000 team members, including more
than 5,000 clinicians, we work compassionately to elevate standards of care for
patients with acute and chronic conditions in all 50 states. Through our
clinical leadership, expertise and national scale, Option Care Health is
reimagining the infusion care experience for patients, customers and team
members. To learn more, please visit our website at optioncarehealth.com.
Investor Contact
Bob Okunski
Vice President, Investor Relations
[email protected]
Forward-Looking Statements - Safe Harbor
This press release contains “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements can be identified by words such as:
“anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,”
“may,” “should,” “will” and similar references to future periods. Examples of
forward-looking statements include, among others, statements the Company may
make regarding the acquisition, future revenues, future earnings, other future
financial results, regulatory developments, market developments, new products
and growth strategies and the effects of any of the foregoing on its future
results of operations or financial condition.
Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on the Company's current beliefs,
expectations and assumptions regarding the future of its business, future plans
and strategies, projections, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are outside of the
Company's control. The Company's actual results and financial condition may
differ materially from those indicated in the forward-looking statements.
Important factors that could cause the Company's actual results and financial
condition to differ materially from those indicated in the forward-looking
statements include, among others, the following: the termination of or
occurrence of any event, change or other circumstances that could give rise to
the termination of the merger agreement, including circumstances requiring the
Company to pay a termination fee pursuant to the merger agreement, or the
inability to complete the proposed transaction on the anticipated terms and
timetable; the inability to complete the proposed transaction due to the failure
to obtain approval of the stockholders of the Company or to satisfy any other
condition to closing in a timely manner or at all, or the risk that a regulatory
approval that may be required for the proposed transaction is delayed, is not
obtained or is obtained subject to conditions that are not anticipated; costs
related to the proposed transaction, including from potential litigation
relating to the proposed transaction; the risk that restrictions on the
operation of the Company’s business during the pendency of the proposed
transaction may impact the Company’s ability to pursue certain business
opportunities or strategic transactions or undertake certain actions the Company
might otherwise have taken; the risk that any announcements relating to the
proposed transaction could have adverse effects on the market price of the
Company’s common stock, credit ratings or operating results; the risk that the
proposed transaction and its announcement could have an adverse effect on the
ability of the Company to retain and hire key personnel, retain customers and
maintain relationships with business partners, suppliers and customers; the
diversion of management’s time and attention from ordinary course business
operations to completion of the proposed transaction; changes in laws,
regulations or trade policies applicable to its business model; loss of
relationships with managed care organizations and other non-governmental third
party payers; changes in the pharmaceutical industry, including limiting or
discontinuing research, development, production and marketing of pharmaceuticals
compatible with its services; changes in market conditions and receptivity to
its services and offerings; and pending and future litigation or potential
liability for claims not covered by insurance. The foregoing review of important
factors should not be construed as exhaustive. Additional information concerning
risks, uncertainties and assumptions can be found in the Company’s filings with
the SEC, including the risk factors discussed in the Company’s most recent
Annual Report on Form 10-K, as updated by the Company’s Quarterly Reports on
Form 10-Q and future filings with the SEC.
Any forward-looking statement made by the Company in this press release is based
only on information currently available to it and speaks only as of the date on
which it is made. The Company undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or
otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally
accepted accounting principles (GAAP), the Company is also reporting Adjusted
net income, Adjusted EBITDA and Adjusted diluted earnings per share ("EPS"),
which are non-GAAP financial measures. These adjusted measures are not
measurements of financial performance under GAAP and should not be used in
isolation or as a substitute or alternative to net income, EPS, or any other
performance measure derived in accordance with GAAP, or as a substitute or
alternative to cash flow from operating activities or a measure of the Company’s
liquidity. In addition, the Company's definitions of Adjusted net income,
Adjusted EBITDA, and Adjusted diluted EPS may not be comparable to similarly
titled non-GAAP financial measures reported by other companies. As defined by
the Company: (i) Adjusted net income represents net income before intangible
asset amortization expense, stock-based compensation expense, loss on
extinguishment of debt, and restructuring, acquisition, integration and other
expenses, net of tax adjustments, (ii) Adjusted EBITDA represents net income
before net interest expense, income tax expense, depreciation and amortization,
stock-based compensation expense, loss on extinguishment of debt, and
restructuring, acquisition, integration and other expenses, and (iii) Adjusted
diluted EPS represents Adjusted net income divided by weighted average common
shares outstanding, diluted. As part of restructuring, acquisition, integration
and other expenses, the Company may incur significant charges such as the write
down of certain long‑lived assets, temporary redundant expenses, professional
fees, certain litigation expenses and reserves related to acquired businesses,
potential retention and severance costs and potential accelerated payments or
termination costs for certain of its contractual obligations. Management
believes that these adjusted measures provide useful supplemental information
regarding the performance of Option Care Health’s business operations and
facilitate comparisons to the Company’s historical operating results. The
Company has not reconciled Adjusted EBITDA guidance to net income or Adjusted
diluted EPS guidance to GAAP diluted EPS as management believes creation of this
reconciliation would not be practicable due to the uncertainty regarding, and
potential variability of, material reconciling items. Full reconciliations of
each historical adjusted measure to the most comparable GAAP financial measure
are set forth below.
Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 299,093 $ 232,624
Accounts receivable, net 505,568 473,566
Inventories 408,045 471,149
Prepaid expenses and other
current 99,385 87,629
assets
Total current assets 1,312,091 1,264,968
NONCURRENT ASSETS:
Property and equipment, net 139,035 139,236
Intangible assets, net 19,394 21,897
Referral sources, net 261,975 287,281
Goodwill 1,606,743 1,606,743
Other noncurrent assets 137,029 135,644
Total noncurrent assets 2,164,176 2,190,801
TOTAL ASSETS $ 3,476,267 $ 3,455,769
LIABILITIES AND
STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable $ 670,676 $ 639,829
Other current liabilities 179,854 189,519
Total current liabilities 850,530 829,348
NONCURRENT LIABILITIES:
Long-term debt, net of
discount,
deferred financing costs 1,151,054 1,154,052
and current
portion
Other noncurrent 150,205 145,976
liabilities
Total noncurrent 1,301,259 1,300,028
liabilities
Total liabilities 2,151,789 2,129,376
STOCKHOLDERS' EQUITY 1,324,478 1,326,393
TOTAL LIABILITIES AND
STOCKHOLDERS' $ 3,476,267 $ 3,455,769
EQUITY
Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
Three Nine
Months Months
Ended Ended
Septem… Septem…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
NET $ 1,493,… $ 1,435,0… $ 4,286,… $ 4,184,0…
REVEN…
COST
OF 1,208,… 1,162,1… 3,472,… 3,379,0…
REVEN…
GROSS 284,974 272,902 814,239 804,997
PROFIT
OPERA…
COSTS
AND
EXPEN…
Selli…
gener…
and 171,998 167,470 503,063 497,744
admin…
expen…
Restr…
acqui…
integ… 5,640 4,634 13,796 12,570
and
other
Depre…
and 18,120 16,291 50,479 48,278
amort…
expen…
Total
opera… 195,758 188,395 567,338 558,592
expen…
OPERA… 89,216 84,507 246,901 246,405
INCOME
OTHER
INCOME
(EXPE…
Inter…
expen… -12,875 -14,146 -40,199 -41,824
net
Other, 2,560 -1,394 7,189 -3,197
net
Total
other -10,315 -15,540 -33,010 -45,021
(expe…
income
INCOME
BEFORE 78,901 68,967 213,891 201,384
INCOME
TAXES
INCOME
TAX 21,468 17,151 57,202 52,303
EXPEN…
NET $ 57,433 $ 51,816 $ 156,689 $ 149,081
INCOME
Earni…
per $ 0.38 $ 0.32 $ 1.02 $ 0.91
share,
basic
Earni…
per $ 0.38 $ 0.32 $ 1.02 $ 0.91
share,
dilut…
Weigh…
avera…
shares 149,788 161,829 153,099 163,393
outst…
basic
Weigh…
avera…
shares 150,491 163,086 153,932 164,602
outst…
dilut…
Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
Nine Months Ended
CASH FLOWS FROM September 30,
OPERATING ACTIVITIES: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 156,689 $ 149,081
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 52,874 50,374
amortization expense
Other non-cash 54,243 57,401
adjustments
Changes in operating
assets and
liabilities:
Accounts receivable, -32,002 -55,430
net
Inventories 63,104 -24,899
Prepaid expenses and
other current -14,933 24,694
assets
Accounts payable 31,824 10,224
Accrued compensation
and employee -8,069 8,338
benefits
Other -17,518 2,773
Net cash provided by
operating 286,212 222,556
activities
CASH FLOWS FROM
INVESTING ACTIVITIES:
Acquisition of -26,805 -27,661
property and equipment
Business acquisitions,
net of cash — -117,247
acquired
Other investing -877 -2,529
activities
Net cash used in -27,682 -147,437
investing activities
CASH FLOWS FROM
FINANCING ACTIVITIES:
Purchase of company
stock and related -170,545 -214,887
excise taxes
Proceeds from issuance — 229,472
of debt
Retirement of debt — -180,239
obligations
Other financing -21,516 -12,208
activities
Net cash used in -192,061 -177,862
financing activities
NET INCREASE
(DECREASE) IN CASH AND 66,469 -102,743
CASH
EQUIVALENTS
Cash and cash
equivalents - 232,624 412,565
beginning of
period
CASH AND CASH
EQUIVALENTS - END OF $ 299,093 $ 309,822
PERIOD
Schedule 4
OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 57,433 $ 51,816 $ 156,689 $ 149,081
income
Intere…
expens… 12,875 14,146 40,199 41,824
net
Income
tax 21,468 17,151 57,202 52,303
expense
Deprec…
and 18,837 17,048 52,874 50,374
amorti…
expense
EBITDA 110,613 100,161 306,964 293,582
EBITDA
adjust…
Stock-…
incent… 9,331 11,125 27,912 30,638
compen…
expense
Loss on
exting… — 4,744 — 4,744
of debt
Restru…
acquis…
integr… 4,656 3,468 11,976 16,318
and
other
(1)
Adjust… $ 124,600 $ 119,498 $ 346,852 $ 345,282
EBITDA
Net $ 57,433 $ 51,816 $ 156,689 $ 149,081
income
Intang…
asset 9,269 9,269 27,808 27,663
amorti…
expense
Stock-…
incent… 9,331 11,125 27,912 30,638
compen…
expense
Loss on
exting… — 4,744 — 4,744
of debt
(2)
Restru…
acquis…
integr… 4,656 3,468 11,976 16,318
and
other
(1)
Total
pre-tax 23,256 28,606 67,696 79,363
adjust…
Tax
adjust… -6,298 -7,183 -18,075 -20,634
(3)
Adjust…
net $ 74,391 $ 73,239 $ 206,310 $ 207,810
income
Earnin…
per $ 0.38 $ 0.32 $ 1.02 $ 0.91
share,
diluted
Adjust…
earnin…
per $ 0.49 $ 0.45 $ 1.34 $ 1.26
share,
diluted
Weight…
average
common 150,491 163,086 153,932 164,602
shares
outsta…
diluted
(1) Restructuring, acquisition, integration and other includes $5,640 and
$13,796 of operating expenses for the three and nine months ended September 30,
2026, respectively. Restructuring, acquisition, integration and other includes
$4,634 and $12,570 of operating expenses for the three and nine months ended
September 30, 2025, respectively.
(2) Beginning with the three months ended September 30, 2025, adjusted net
income excludes loss on extinguishment of debt on a prospective basis, which has
been immaterial in prior periods.
(3) Tax adjustments for the three and nine months ended September 30, 2026 and
2025 include the estimated income tax effect on non-GAAP adjustments based on
the effective tax rate.